Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.

NCT01589146 is registered in ClinicalTrials.gov with University Of Perugia as lead sponsor.

NCT NCT01589146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01589146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Lead sponsor
University Of Perugia
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2010
Completion date
Not reported
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

from surgery in the two study groups., prophylaxis given for 8±2 days after planned laparoscopic, safety of extended 4-week heparin prophylaxis compared to, surgery for colorectal cancer., the clinical benefit will be evaluated as the difference in, the incidence of vte or vte-related death occurring within 30 days, the primary study objective is to assess the efficacy and